June 2023 in “Clinica Chimica Acta” Finasteride and dutasteride effectively reduce DHT in hair, which may help evaluate their treatment success for hair loss.
111 citations
,
August 2015 in “Reviews in Endocrine and Metabolic Disorders” 5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.
1 citations
,
December 2009 in “Asian Journal of Research in Chemistry” The methods accurately measure Finasteride and Tamsulosin in tablets.
6 citations
,
December 1996 in “The Journal of Clinical Pharmacology” Terazosin and finasteride together cause no major issues.
34 citations
,
July 1993 in “PubMed” August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
1 citations
,
September 2016 in “Acta Chromatographica” Created method to measure doxazosin mesylate and finasteride together.
7 citations
,
January 2021 in “The Journal of Sexual Medicine” Testosterone with dutasteride improves muscle strength and body composition in trans men.
1 citations
,
September 2023 in “Journal of The American Academy of Dermatology” Low dose oral minoxidil can help with hair loss when used alone.
February 2020 in “Definitions”
February 2025 in “Journal of Pre-Clinical and Clinical Research” The combination of finasteride, dutasteride, and minoxidil is generally safe for treating male hair loss with minimal side effects.
June 2019 in “Reactions Weekly”
January 2018 in “Sohag Medical Journal” Combining topical dutasteride with microneedling is more effective for hair growth than microneedling alone.
March 2025 in “Journal of the American Academy of Dermatology” Dutasteride and finasteride do not increase mood disorder risk in men with hair loss.
1 citations
,
August 2025 in “Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine” BMI should be considered in future research on dutasteride's effects on fertility.
40 citations
,
April 1999 in “Drugs” Finasteride treats enlarged prostate, improves urinary flow, but may cause sexual side effects.
August 2011 in “SpringerReference”
31 citations
,
September 2008 in “International Journal of Andrology” 5-alpha-reductase inhibitors may cause a low incidence of erectile dysfunction that decreases over time.
December 2025 in “The AAPS Journal” Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.
60 citations
,
December 1998 in “Clinical Pharmacology & Therapeutics” Both drugs lower DHT levels, with GI198745 being more effective.
2 citations
,
April 2016 in “Journal of The American Academy of Dermatology” Dutasteride more effective than finasteride for hair growth; SM04554 safe and potentially effective for hair loss.
January 2026 in “Journal of the American Academy of Dermatology” 5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.
January 2023 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” Combining Finasteride and Minoxidil effectively treats hair loss in middle-aged men.
5 citations
,
November 2020 in “medRxiv (Cold Spring Harbor Laboratory)” 5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
2 citations
,
December 2006 in “Lancet Oncology” Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.
January 2018 in “Our Dermatology Online” Dutasteride injections can help hair growth in androgenic alopecia but need more research for long-term use.
April 2017 in “The journal of sexual medicine” 5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.
69 citations
,
August 2008 in “Journal of The European Academy of Dermatology and Venereology” Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.
Finasteride and dutasteride are not recommended for feminizing therapy due to limited effectiveness and potential risks.